In Vivo Base Editing of PCSK9: Early Clinical Data from VERVE-102 and the Path Toward Durable LDL-C Control

2026 Open access

Read full text

Authors: Abraham Samuel Finny

DOI: 10.59350/ppf5a-hvf03

Cited by: 2

References: 9

Abstract

Phase 1b data from Heart-2 show sustained PCSK9 suppression and LDL-C lowering after a single genomic intervention

Lipoproteins and Cardiovascular Health Cardiomyopathy and Myosin Studies Viral Infections and Immunology Research

References 9